Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies

European Respiratory Journal

Volumn 10, Issue 12, 1997, Pages 2907-2912

  Sauty, A ^a   Rochat, Th ^a   Schoch, O D ^b   Hamacher, J ^a   Kurt, A M ^a   Dayer, J M ^b   Nicod, L P ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b St Gallen Hospital   (Switzerland)

Author keywords

Anti Jo 1; CD8+ lymphocyte; Inflammatory myositis; Interstitial lung disease

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD8 ANTIGEN; CYCLOSPORIN; CYTOTOXIC AGENT; STEROID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION TEST; PRIORITY JOURNAL; TRANSBRONCHIAL BIOPSY;

AGED; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AZATHIOPRINE; BIOPSY, NEEDLE; BRONCHOALVEOLAR LAVAGE FLUID; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PULMONARY FIBROSIS; STEROIDS;

EID: 0031434172     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10122907     Document Type: Article

References (30)

1. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15: 168-178.
2. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988; 18: 29-37.
3. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991; 70: 360-374.
4. Tarsoff IN. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am 1994; 20: 857-880.
5. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23: 881-888.
6. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. Arthritis Rheum 1983; 26: 604-611.
7. Bernstein RM, Morgan SH, Chapman J, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 1984; 289: 151-152.
8. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol 1984; 11: 663-665.
9. Marguerie C, Bunn CC, Beynon HLC, et al. Polymyositis, pulmonary fibrosis and autoantibodies to amino-tRNA synthetase enzymes. Q J Med 1990; 77: 1019-1038.
10. Chan WM, Lau CS, Wang E, Peh WCG. Anti-Jo-1 syndrome presenting as cryptogenic organizing pneumonia. Respir Med 1995; 89: 639-641.
11. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995; 38: 1519-1523.
12. Schwarz MI, Sutarik JM, Nick JA, Leff JA, Emlen JW, Tuder RM. Pulmonary capillaritis and diffuse alveolar hemorrhage. A primary manifestation of polymyositis. Am J Respir Crit Care Med 1995; 151: 2037-2040.
13. Nash P, Schrieber L, Webb J. Interstitial lung disease as the presentation of anti-Jo-1 positive polyomyositis. Clin Rheumatol 1987; 6: 282-286.
14. Löhr H-F, Böcher WO, Hermann E, et al. Interstitial alveolitis as early manifestation of anti-Jo-1 polymyositis. Z Rheumatol 1993; 52: 307-311.
15. Flammang d'Ortho MP, Cadranel J, Milleron B, et al. Atteintes pulmonaires interstitielles des polymyosites (PM) et dermatopolymyosites (DP). A propos de 3 observations. Revue de la littérature. Rev Pneumol Clin 1991; 47: 29-36.
16. Chmiel JF, Wessel HU, Targoff IN, Pachman LM. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol 1995; 22: 762-765.
17. The BAL cooperative group steering committee. Am Rev Respir Dis 1990; 141: S199.
18. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med 1990; 88: 241-251.
19. Goldstein R, Duvic M, Targoff IN, et al. HLA-D region genes associated with autoantibody responses to histidyltransfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum 1990; 33: 1240-1248.
20. Targoff IN, Reichlin M. Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity. J Immunol 1987; 138: 2874-2882.
21. Dalakas MC. Current treatment of the inflammatory myopathies. Curr Opin Rheumatol 1994; 6: 595-601.
22. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993; 94: 379-387.
23. Dankó K, Szegedi G. Cyclosporin A treatment of dermatomyositis. Arthritis Rheum 1991; 34: 933-934.
24. Mehregan DR, Su D. Cyclosporine treatment for dermatomyositis/polymyositis. Cutis 1993; 51: 59-61.
25. Grau JM, Herrero C, Casademont J, Fernandez-Sola J, Urbano-Marquez A. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 1994; 21: 381-382.
26. McCune J, Vallance DK, Lynch JP 3rd. Immunosuppressive drug therapy. Curr Opin Rheumatol 1994; 6: 262-272.
27. Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol 1989; 16: 1592-1596.
28. Rowen AJ, Reichel J. Dermatomyositis with lung involvement, successfully treated with azathioprine. Respiration 1983; 44: 143-146.
29. Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol 1987; 14: 1045-1047.
30. Moolman JA, Bardin PG, Rossouw DJ, Jouberl JR. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592-595.